Pasero G, Pellegrini P, Ciompi M L, Colamussi V, Barbieri P, Mazzoni M R
Rev Rhum Mal Osteoartic. 1980 Mar;47(3):163-8.
A study of patients with rheumatoid arthritis permitted us to note the interest of tiopronine (sulfhydryl compound of the d-penicillamine type) in the basic treatment of rheumatoid arthritis. The dose of the drug was on average, 1 gram daily, which, in one series of patients, was administered at the start of treatment and in another series, with an increase of dosage of 250 mg every 20 days. The results, judged by the reduction of the Ritchie and Lee index, of the E.R.S. and the steroid and non-steroid anti-inflammatory requirements, are good (very good and good) in 47% of cases. These patients were in an advanced stage of the disease and there had been numerous therapeutic failures. Side effects similar to those observed during treatment with D-penicillamine were present in 38% of cases, and in 31% required stopping treatment. It is likely that the frequency of stopping treatment for side effects was definitely exaggerated. The place of this new drug in the basic treatment of rheumatoid arthritis requires further study by a double blind test with D-penicillamine, and this is at present in progress.
一项针对类风湿性关节炎患者的研究使我们注意到了硫普罗宁（d-青霉胺类巯基化合物）在类风湿性关节炎基础治疗中的价值。该药的平均剂量为每日1克，在一组患者中，于治疗开始时给药；在另一组患者中，每20天增加250毫克剂量。根据里奇和李指数、欧洲抗风湿病联盟（E.R.S.）评分以及类固醇和非类固醇抗炎药物需求的降低情况判断，47%的病例结果良好（非常好和良好）。这些患者处于疾病晚期，此前有过多次治疗失败。38%的病例出现了与使用D-青霉胺治疗期间观察到的类似副作用，31%的病例需要停药。因副作用而停药的频率很可能被严重夸大了。这种新药在类风湿性关节炎基础治疗中的地位需要通过与D-青霉胺的双盲试验作进一步研究，目前该试验正在进行中。
